Alkermes
alkermes design approach build functional in the tumor through engineered tumor targeted subunits key design considerations and challenges split to create functionally inactive subunits to be directed to the tumor engineer subunits to address inherent stability challenges in production and enhance the affinity of non linked and subunits identify unique tumor targeting antigen and generate proprietary antibodies certain proteins exhibit increased expression in tumors relative to normal tissue and can be leveraged to target to tumors with high specificity produce novel engineered tumor targeted fusion proteins using proprietary antibodies subunits can be fused to proprietary antibody against unique tumor antigen fusion protein engineering non targeted engineered inactive subunit tumor targeting antibody tumor targeted subunits | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
104 of 144
Related slides by other companies
Immatics
Investor Presentation
November 2023
potency of our proprietary format | Immatics
Adagio Therapeutics
Investor Presentation
November 2022
robust pipeline of engineered antibodies for treatment and prevention of viral diseases | Adagio Therapeutics
Adagio Therapeutics
Investor Presentation
September 2022
robust pipeline of engineered antibodies for treatment and prevention of viral diseases | Adagio Therapeutics
Adagio Therapeutics
Investor Presentation
September 2022
our vision | Adagio Therapeutics
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io